Evolution of echocardiographic parameters during tafamidis therapy in patients with transthyretin cardiac amyloidosis: a real-world cohort study

30 August 2026 (12:15 - 13:00)

Organised by:

Video

Abstract

Slides

About the speakers

Associate Professor Alexandros Briasoulis

National & Kapodistrian University of Athens Medical School, Athens (Greece)

Miss Christina Konstantaki

Alexandra University Hospital, Athens (Greece)

6 More presentations in this session

Left atrial–left ventricular coupling index as a novel diagnostic and prognostic marker in HFpEF: systematic review and meta-analysis

Doctor C. Fischer Bacca (Rio do Sul, BR)

Abstract Slides Video

Prognostic role of the left atrioventricular coupling index in patients with aortic regurgitation

Doctor M. Rojas (Santiago, CL)

Abstract Slides Video

Changes in diastolic function after TAVI: trends in conventional parameters and the role of left atrial reservoir strain

Doctor E. Eerola (Uppsala, SE)

Abstract Slides Video

Beyond the two cusps: disparities in echocardiographic assessment and guideline adherence in bicuspid aortic valve management in Argentina

Doctor M. Carrero (Buenos Aires, AR)

Abstract Slides Video

Epicardial adipose tissue thickness measured by echocardiography is associated with metabolic syndrome in a surgical cohort of patients with coronary artery disease and valvular heart disease

Mr F. Opdahl (Oslo, NO)

Abstract Slides Video

Access the full session

Valvular disease, diastolic function, atrioventricular coupling, and beyond

The Event

ESC Congress 2026

30 August 2026 12:15 CET

You may be interested in

Congress Presentation

Structural and functional echocardiographic characterisation and prognostic determinants in real-world transthyretin amyloid cardiomyopathy patients on standard of care

31 August 2026

Congress Presentation

Pathophysiological impact of one year of tafamidis in patients with transthyretin cardiac amyloidosis

30 August 2026

Congress Presentation

Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.

12 May 2024

Congress Presentation

Comprehensive assessment of disease status in ATTRwt-CM: Integrating serum transthyretin levels with clinical parameters using stabilizer therapy

30 August 2026

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

ESC 365 is supported by

Explore sponsored resources